Prof Jarad Martin

Radiation Oncologist who treats and researches #prostatecancer, gastrointestinal cancers & benign diseases. Dabbles in #mathematics. Views my own.

[ASTRO @ASTRO_org]

TODAY! ASTRO’s first ever Functional Radiation Medicine Grand Rounds

Join us on today, Thursday, Feb. 26 at 4:00 p.m. ET

Jarad Martin, PhD, ChB, MB, and Peter Gorayski, BMBS, present emerging evidence on the application of low-dose radiation therapy for nonmalignant conditions such as Osteoarthritis, Plantar Fasciitis, and Ledderhose Disease. @DocJarad @PeterGorayski

Organized by ASTRO's new Functional Radiation Medicine Task Force.

Register here for this FREE event: https://t.co/X3pQLPBwHL

[ASTRO @ASTRO_org]

Register FREE for ASTRO’s first Functional Radiation Medicine Grand Rounds
New Date - Join us on Thursday, February 26 at 4:00 p.m. ET!

Jarad Martin, PhD, ChB, MB, and Peter Gorayski, BMBS, present emerging evidence on the application of low-dose radiation therapy for nonmalignant conditions such as Osteoarthritis, Plantar Fasciitis, and Ledderhose Disease. @DocJarad @PeterGorayski

Organized by ASTRO's new Functional Radiation Medicine Task Force.

Register FREE for this inaugural event: https://t.co/X3pQLPBwHL

[ASTRO @ASTRO_org]

Register FREE for ASTRO’s first Functional Radiation Medicine Grand Rounds

Join us on Wednesday, February 25 at 4:00 p.m. ET as Jarad Martin, PhD, ChB, MB, and Peter Gorayski, BMBS, present emerging evidence on the application of low-dose radiation therapy for nonmalignant conditions such as Osteoarthritis, Plantar Fasciitis, and Ledderhose Disease. @DocJarad @PeterGorayski

Organized by ASTRO's new Functional Radiation Medicine Task Force.

Register FREE for this inaugural event: https://t.co/X3pQLPBwHL

[ANZUP @ANZUPtrials]

Today our 2025 @ANZUPtrials Idea Generation Workshops continue with #ProstateCancer today led by #ProfLisaHorvath & @DocJarad with over 10 concepts being presented #ANZUPconcepts @PCFA @CancerAustralia @Prof_IanD

[Sameer Keole @SameerKeoleMD]

Thanks for sharing!

The @ASTRO_org 2025 AM in San Francisco (Sep 27-Oct 1) will have a 3 hr symposium on Sun featuring RT for non-malignant disease, including cardiac. Your fellow Aussie, @DocJarad, is helping put it together. See you this Fall, if not sooner!

[Prof Jarad Martin @DocJarad]

ProPSMA - the gift that keeps on giving! Great to be part of such an impactful collaboration.

[Michael Hofman @DrMHofman]

Longer follow-up from our landmark ProPSMA study just out @EurUrolOncol:

PSMA nodal status is prognostic! At 3 years 70% of patients without nodal involvement (N0) disease free, vs. only 46% if N1

CT-defined nodal status is not prognostic.

Read the details here: https://t.co/OWCrc3ui8P

Super team: @declangmurphy @veerukasi @ButeauJames @lawrentschuk @mj_robbo @DocJarad @mfrydenberg @DrAIravani

ProPSMA sponsored by @PeterMacCC
Funded by @PCFA @MovemberAUS
@pros_tic supported by @PCF_Science

[Nicholas van As @nickva1]

Delighted to share the results of #PACE B trial, published in @NEJM today
5 fraction SBRT is non inferior to CRT!
https://t.co/9ja6OZFRab
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa

[Prof Jarad Martin @DocJarad]

Brachytherapy doses of radiotherapy delivered non-invasively for prostate cancer with 94.1% 5-year control and low rates of significant toxicity. Now being investigated in randomised trials such as @TROGfightcancer NINJA and @GETUG_Unicancer PEACE 7.

[European Urology Oncology @EurUrolOncol]

Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial by @drericwegener et al

https://t.co/7KXd5JKjob

#UroSoMe #MedTwitter #EUO

[UroToday.com @urotoday]

#STORM trial examines elective nodal radiotherapy in treating #ProstateCancer recurrence. @piet_ost @ugent joins @zklaassen_md @GACancerCenter to discuss, emphasizing that ENRT offers longer disease-free periods and lower pelvic recurrence rates compared to SBRT. #WatchNow > https://t.co/F67k377bNP

[Alison Tree 💙 @alison_tree]

Tell me again why we can’t use renal SBRT in the UK?!? 100% local control is hard to beat. Masterclass by @_ShankarSiva #ASTRO24

[Prof Jarad Martin @DocJarad]

I struggle with when to consider testosterone replacement for symptomatic men with controlled disease after ADT. After either six or 18 months of ADT, spontaneous recovery is rare after the two year mark, so some great data to inform shared decision making.

[Amar Kishan @AmarUKishan]

Pleased to share the newest MARCAP publication, out in @EUplatinum -- the TRANSPORT analysis of T recovery after ADT for localized PCa, led by @weeloonong and Tahmineh Romero
Free share link: https://t.co/ssaSqPw8iC

[Pierre Blanchard, MD @PBlanchardMD]

Transdermal estradiol as a new option for testosterone lowering vs LHRHa :

similar MFS & OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...)

Open Qs:
1. efficacy vs antagonists
2. combination with other drugs (ARPI, PARPi) or RT

#ESMO2024

[Nicholas van As @nickva1]

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦@DrTolan⁩ @alison_tree⁩ ⁦@cpeedell⁩ @DrAndrewLoblaw⁩ ⁦@EmmaHall71⁩ @ProfJOSullivan⁩ https://t.co/HlFxb3jegQ

[David Kirsch, MD, PhD @DKirschMDPhD]

Congratulations @ldawsonmd @RadMedPM @pmcancercentre @UHN @UofTDRO and colleagues across Canada for publishing CCTG HE1 in @TheLancetOncol establishing single fraction RT as an effective palliative treatment for painful liver cancer.

@CDNCancerTrials

https://t.co/aFw3lpyv7Z

[Quite Interesting @qikipedia]

Word of the Day: PSEUDOGLOT (neologism) - one who knows a few basic words in many languages and pretends to be a polyglot.

[Prof Jarad Martin @DocJarad]

@drkeithsiau Please, please, let’s stop calling a non-inflammatory condition ‘proctitis’. Radiation Associated Vascular Ectasia is da money @stevenbollipo @SultanMahmoodMD https://t.co/QcvLLHmDkM

[Prof Jarad Martin @DocJarad]

@NiuSanford @SprakerMDPhD We think the three month PET is highly prognostic, with a meta-analysis from 2015 to support, and evidence only stronger since. https://t.co/RrGixFOELV

[Prof Jarad Martin @DocJarad]

@gnioannou @stevenbollipo Great start. We might now consider some local therapy like SBRT as an attempt to consolidate disease control before it becomes refractive to systemic therapy. 🤔

[Prof Jarad Martin @DocJarad]

Great to see vHDRB going mainstream. Here is our data for 20Gy/2# boost - 94% efficacy, and low toxicity. Experimental arm in ongoing RCTs NINJA and PEACE 7.
https://t.co/6Zgh00W6Z5

[Sean Collins Prostate SBRT @ USF Health @SbrtSean]

EBRT Plus Prostate SBRT Boost (19 Gy in 2 Fxs) has been Added to the NCCN Guidelines for Unfavorable Intermediate to Very High Risk Prostate Cancer!

[Dr. Andrew Loblaw @DrAndrewLoblaw]

100% agree @DrSpratticus
Here's a popular #HIFU company's web posting...
Vs data they reference vs other published data... (note their ref has no RP nor RT data). Yes failure def'n different for RP vs RT but drives salvage = more toxicity
Maybe they need to hire new webmaster?